Zealand Pharma A/S
F:22Z
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Z
|
Zealand Pharma A/S
F:22Z
|
DK |
|
N
|
Netum Group Oyj
F:79J
|
FI |
Intrinsic Value
The intrinsic value of 
Zealand Pharma A/S (22Z) under the Base Case is 27.86 EUR per share.
Compared with the current market price of 30.11 EUR, the stock appears
Overvalued by 7% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Zealand Pharma A/S Does
Zealand Pharma is a Danish biotechnology company that discovers and develops peptide-based medicines. It does not sell consumer products; it builds drug candidates for diseases such as metabolic disorders and some rare conditions, then works to move them through testing and approval. Its core business is making medicines that can act like natural hormones and signaling molecules in the body, which is a useful approach when a disease is caused by a missing or weak biological signal.
- Headquarters
- Denmark DK
- Employees
- 544
- IPO date
- Nov 1, 2010
Revenue & Expenses Breakdown
Zealand Pharma A/S
Earnings Waterfall
Zealand Pharma A/S
The intrinsic value for Zealand Pharma A/S (22Z) under the Base Case is 27.86 EUR.
Compared with the current market price of 30.11 EUR, the stock appears Overvalued by 7% .